This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Ronco succeeds Dr. Christine Dingivan, who will now serve as a senior advisor to Executive Chairman Sastry Chilukuri
Strides Pharma Science Limited to acquire 100% in Strides Pharma Services Pvt Ltd.
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
This four-day course is designed for professionals in the pharmaceutical, nutraceutical, and related industries
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Subscribe To Our Newsletter & Stay Updated
